Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun 21;3(6):100668.
doi: 10.1016/j.xcrm.2022.100668.

Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer

Igor Makhlin  1 , Angela DeMichele  2
Affiliations
Comment

Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer

Igor Makhlin et al. Cell Rep Med. .

Abstract

In DESTINY-Breast 03, Trastuzumab Deruxtecan, a HER2-specific antibody-drug conjugate, proved superior to T-DM1 in patients with HER2+ metastatic breast cancer progressing on taxane and trastuzumab.1 This study supported its recent approval as second-line therapy in HER2+ metastatic breast cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Comment on

  • Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
    Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.

References

    1. Cortés J., Kim S.-B., Chung W.-P., Kim S.-A., Park Y.H., Hegg R., et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N. Engl. J. Med. 2022;386:1143–1154. doi: 10.1056/NEJMOA2115022/SUPPL_FILE/NEJMOA2115022_DATA-SHARING.PDF. - DOI - PubMed
    1. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., Mcguire W.L. Human breast cancer: Correlation of relapse and survival with Amplification of the HER-2/neu oncogene. New Ser. 1987;235:177–182. doi: 10.1126/science.3798106. - DOI - PubMed
    1. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that Overexpresses HER2. N. Engl. J. Med. 2001;344:783–792. doi: 10.1056/nejm200103153441101. - DOI - PubMed
    1. Perez E.A., Romond E.H., Suman V.J., Jeong J.H., Sledge G., Geyer C.E., Jr., Martino S., Rastogi P., Gralow J., Swain S.M., et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 - positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J. Clin. Oncol. 2014;32:3744–3752. doi: 10.1200/JCO.2014.55.5730. - DOI - PMC - PubMed
    1. Hurvitz S., Kim S.-B., Chung W.-P., Im S.-A., Park Y.H., Hegg R., Kim M.-H., Tseng L.-M., Petry V., Chung C.-F., et al. SABCS 2021. 2021. Trastuzumab deruxtecan (T-DXd; DS-8201a) vs trastuzumab emtansine (T-DM1) in patients with HER2+ metastatic breast cancer. 2021 San Antonio Breast Cancer Symposium. GS3-01.

MeSH terms